EGFR and neoplasm: In conclusion, the molecular landscape of GBMs with at least 30% GCs is dominated by tumor suppressor impairment represented by alterations in TP53/MDM2 and RB1/CDKN2A/CDK4 pathways, associated with EGFR amplification in more aggressive cases.